Weekly Research Analysts’ Ratings Updates for Alkermes (ALKS)

A number of firms have modified their ratings and price targets on shares of Alkermes (NASDAQ: ALKS) recently:

• 6/29/2026 – Alkermes had its price target raised by Wells Fargo & Company from $44.00 to $65.00. They now have an “overweight” rating on the stock.
• 6/29/2026 – Alkermes had its “underperform” rating reaffirmed by Bank of America Corporation.
• 6/24/2026 – Alkermes had its price target raised by Needham & Company LLC from $54.00 to $61.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Alkermes had its price target raised by TD Cowen from $42.00 to $50.00. They now have a “buy” rating on the stock.
• 6/18/2026 – Alkermes had its “neutral” rating reaffirmed by HC Wainwright.
• 6/18/2026 – Alkermes had its price target raised by Needham & Company LLC from $50.00 to $54.00. They now have a “buy” rating on the stock.
• 6/9/2026 – Alkermes had its price target raised by Royal Bank Of Canada from $45.00 to $56.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Alkermes had its price target raised by Robert W. Baird from $45.00 to $48.00. They now have an “outperform” rating on the stock.
• 5/11/2026 – Alkermes was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 5/6/2026 – Alkermes had its price target raised by UBS Group AG from $42.00 to $48.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Alkermes had its price target raised by Wells Fargo & Company from $43.00 to $44.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Alkermes had its price target raised by Needham & Company LLC from $45.00 to $50.00. They now have a “buy” rating on the stock.

Insider Activity

In related news, Director Christopher I. Wright sold 2,000 shares of the company’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $45.10, for a total transaction of $90,200.00. Following the completion of the sale, the director directly owned 25,680 shares in the company, valued at $1,158,168. This represents a 7.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $35.51, for a total value of $319,590.00. Following the sale, the executive vice president directly owned 85,389 shares in the company, valued at approximately $3,032,163.39. The trade was a 9.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 35,102 shares of company stock worth $1,310,828. 4.59% of the stock is currently owned by company insiders.

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.